Werkgroep Cardiologische centra Nederland

STEP-HFpEF (Recruiting)

To evaluate the effect of semaglutide (GLP-1) in patients with obesity and chronic HFpEF on heart failure disease-specific symptoms, health status and quality of life, when compared with placebo
Medicine
Semaglutide
Population
Heart failure
Phase
III
Starting year
2019

Director of Study

dr. C.A. da Fonseca (Cardioloog)
Leeuwarden, Medisch Centrum Leeuwarden